Back to search

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Data up to Jan 2025

Published2013
Citations168
References19

Total Citations Per Year

Abstract

References (19)

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

2009 • 3,433 citations

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

2006 • 1,745 citations

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

2010 • 942 citations

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

2006 • 699 citations

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

2012 • 550 citations

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

2009 • 499 citations

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

2012 • 479 citations

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

2012 • 475 citations

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

2012 • 425 citations

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

2008 • 409 citations

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

2008 • 325 citations

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

2010 • 245 citations

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma

2011 • 159 citations

First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.

2013 • 75 citations

Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence

2010 • 69 citations

Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters

2012 • 37 citations

Biological Prognostic and Predictive Factors in Lung Cancer

2009 • 29 citations

Novel Systemic Therapies for Small Cell Lung Cancer

2008 • 27 citations

Nonaneurysmal Subarachnoid Hemorrhage

2007 • 12 citations

Cited By (0)

No citing papers found in database

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP… (2013) – Clinical Cancer Research | Metascience Observatory Explorer